News
Innovative biotech firm raises $33 million to progress gene therapy treatment for refractory epilepsy
Refractory (meaning a condition that resists treatment) epilepsy is, sadly, a condition that blights the lives of so many of our loved ones.
Refractory (meaning a condition that resists treatment) epilepsy is, sadly, a condition that blights the lives of so many of our loved ones. Thus news released by EpilepsyGTx, a biotechnology company focused on gene therapies to treat refractory epilepsy, caught the eye when it was distributed late last year.
Epilepsy GTx announced that it has raised $33 million in financing to advance its work through clinical trials.
Its gene therapy programme, EPY 201, will be tested in a broad population of patients with focal refractory epilepsy, to establish its effectiveness and safety.
If successful, the company believes that it offers people with focal refractory epilepsy “the prospect of seizure freedom in a single intervention without surgery and the chronic use of multiple antiseizure medicines.”
It’s a bold claim and ambition, but well worth us keeping an eye on the progress they make in the months and years ahead.
News
The latest news, opinion and events from FFES
FFES Our Voices Matter: A Request to be Heard addressed to the Board of Trustees of the Epilepsy Society
We are making this request to the Board of Trustees in the form of a letter, because our attempts to establish lines of communication with the current Board of Trustees have been largely unsuccessful.
Support FFES
Help us bring more to their lives
Every pound donated goes to improving the life of the people who live at the Epilepsy Society, and for the staff who support them.
Your support can change lives
- £12 could pay for two staff vouchers in the Phoenix Cafe
- £50 could pay for new shrubs for our Nature Trail
- £750 could pay for an entire Sunday Sounds concert
- £25 monthly helps us organise future concerts for residents and staff
Giving takes just one minute through JustGiving.
